DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics

** 开发新的蛋白质组学技术，以改善冠心病的早期诊断 **Eliptica有限公司提出了一项为期24个月的工作计划，该计划基于一种新的人工智能增强，超快，低成本的基于质谱（MS）的蛋白质组学技术，该技术由其创始人在弗朗西斯克里克研究所开发，只需要非常少量的血浆就可以进行高质量的人口规模，在项目合作伙伴布鲁克英国有限公司和英国生物银行的支持下，是为了证明我们的平台可以通过将AI应用于人类蛋白质组的大型参考基线来开发对CVD的新见解，从而识别新型多蛋白质组生物标志物（MPPB）我们的MPPB将很容易转化为血液测试，更准确地识别CVD高风险患者（例如心脏病发作的迫在眉睫的风险）或潜在地识别最有可能从特定治疗中受益的患者子集。Eliptica的成立旨在实现精准医疗（即确保正确的患者在正确的时间接受正确的治疗和医疗干预）。

**Developing novel proteomic techniques to improve early diagnostics for Coronary Heart Disease**Eliptica Limited proposes a 24 month programme of works based upon a new technique of AI-enhanced, ultrafast, low-cost mass-spectrometry (MS)-based proteomics that has been developed by its founders at the Francis Crick Institute and requires only very small amounts of blood plasma to perform high-quality, population scale, proteomic experiments.The project objective, with support from project partners Bruker UK Limited and UK Biobank, is to demonstrate that our platform can develop new insights into CVD through the application of AI to a large reference baseline of the human proteome and thus identify novel multi protein panel biomarkers (MPPB's) more quickly and accurately than is currently the case.Our MPPB's will be readily translatable into blood tests that more accurately identify patients at high risk of CVD (e.g. imminent risk of heart attack) or potentially identify the subset of patients most likely to benefit from a particular therapy. Eliptica was founded to enable Precision Medicine (i.e. to ensure the right patients receive the right treatments and medical interventions at the right time).